SANTA CRUZ BIOTECHNOLOGY, INC.

HORMAD2 (S-16): sc-82195

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

HORMAD2 (HORMA domain containing 2) is a 307 amino acid protein that contains one HORMA domain and is expressed in brain, testis and liver with lower levels present in kidney. The gene encoding HORMAD2 maps to human chromosome 22, which houses over 500 genes and is the second smallest human chromosome. Mutations in several of the genes that map to chromosome 22 are involved in the development of Phelan-McDermid syndrome, Neurofibromatosis type 2, autism and schizophrenia. Additionally, translocations between chromosomes 9 and 22 may lead to the formation of the Philadelphia Chromosome and the subsequent production of the novel fusion protein Bcr-Abl, a potent cell proliferation activator found in several types of leukemias.

REFERENCES

1. Gilbert, F. 1998. Disease genes and chromosomes: disease maps of the human genome. Chromosome 22. Genet. Test. 2: 89-97.
2. Schwab, S.G. and Wildenauer, D.B. 1999. Chromosome 22 workshop report. Am. J. Med. Genet. 88: 276-278.
3. Matsuda, A., Suzuki, Y., Honda, G., Muramatsu, S., Matsuzaki, O., Nagano, Y., Doi, T., Shimotohno, K., Harada, T., Nishida, E., Hayashi, H. and Sugano, S. 2003. Large-scale identification and characterization of human genes that activate NFκB and MAPK signaling pathways. Oncogene 22: 3307-3318.
4. Tsilchorozidou, T., Menko, F.H., Lalloo, F., Kidd, A., De Silva, R., Thomas, H., Smith, P., Malcolmson, A., Dore, J., Madan, K., Brown, A., Yovos, J.G., Tsaligopoulos, M., Vogiatzis, N., Baser, M.E., Wallace, A.J. and Evans, D.G. 2004. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. J. Med. Genet. 41: 529-534.
5. Arinami, T. 2006. Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia. J. Hum. Genet. 51: 1037-1045.
6. Paylor, R., Glaser, B., Mupo, A., Ataliotis, P., Spencer, C., Sobotka, A., Sparks, C., Choi, C.H., Oghalai, J., Curran, S., Murphy, K.C., Monks, S., Williams, N., O'Donovan, M.C., Owen, M.J., Scambler, P.J. and Lindsay, E. 2006. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc. Natl. Acad. Sci. USA 103: 7729-7734.
7. Zheng, X., Güller, S., Beissert, T., Puccetti, E. and Ruthardt, M. 2006. Bcr and its mutants, the reciprocal t(9;22)-associated Abl/Bcr fusion proteins, differentially regulate the cytoskeleton and cell motility. BMC Cancer 6: 262.
8. Ahronowitz, I., Xin, W., Kiely, R., Sims, K., MacCollin, M. and Nunes, F.P. 2007. Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum. Mutat. 28: 1-12.
9. Hay, B.N. 2007. Deletion 22q11: spectrum of associated disorders. Semin. Pediatr. Neurol. 14: 136-139.

CHROMOSOMAL LOCATION

Genetic locus: HORMAD2 (human) mapping to 22q12.2; Hormad2 (mouse) mapping to 11 A1.

SOURCE

HORMAD2 (S-16) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping within an internal region of HORMAD2 of human origin.

PRODUCT

Each vial contains 100 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-82195 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

HORMAD2 (S-16) is recommended for detection of HORMAD2 of mouse and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

HORMAD2 (S-16) is also recommended for detection of HORMAD2 in additional species, including equine and canine.

Suitable for use as control antibody for HORMAD2 siRNA (h): sc-75275, HORMAD2 siRNA (m): sc-75276, HORMAD2 shRNA Plasmid (h): sc-75275-SH, HORMAD2 shRNA Plasmid (m): sc-75276-SH, HORMAD2 shRNA (h) Lentiviral Particles: sc-75275-V and HORMAD2 shRNA (m) Lentiviral Particles: sc-75276-V.

Molecular Weight of HORMAD2: 35 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.